According to THE SAGE GROUP, There is a Significant Need for Innovative Endovascular Devices to Treat Below-the-Ankle (BTA) Disease in Critical Limb Ischemia (CLI) Patients
BEAUFORT, SC, August 28, 2024 (BUSINESS WIRE)—Research published by THE SAGE GROUP examines the prevalence, characteristics, comorbidities and consequences of BTA disease, as well as explores the challenges of endovascular revascularization.
BTA disease is characterized by atherosclerotic stenoses and/or occlusions in one or more foot arteries. The pedal artery, plantar arteries (common, medial and lateral) and the plantar arch are among the foot arteries affected.
“Although BTA disease is highly prevalent and associated with poor patient outcomes, it remains misunderstood and undertreated,” stated Mary L. Yost, President of THE SAGE GROUP.
Commenting on the reasons for undertreatment, Yost observed, “Revascularization of the pedal arteries is technically challenging due to small-diameter vessels, vessel tortuosity, medial artery calcification (MAC), thrombus and frequent variants in the pedal circulation. These vessels are also prone to spasm and dissection. The lack of dedicated tools for this vascular territory adds to the problem.”
”Furthermore, there are no guideline recommendations regarding endovascular revascularization of BTA disease. Experts disagree on when to intervene and the extent of reconstruction needed. Furthermore, many interventionalists lack the special skills required to treat pedal disease,” she continued.
“Plain old balloon angioplasty (POBA) remains the standard of care. New more-effective endovascular devices are needed to treat BTA disease,” Yost declared.
CLI is a multilevel, multivessel disease characterized by occlusions and extensive involvement of infrapopliteal and pedal arteries. Patients with BTA disease are more likely to have below-the-knee disease in the tibial, peroneal and posterior tibial arteries rather than in the femoral or iliac arteries. Isolated BTA disease appears to be rare.
About the Report: Below-the-Ankle Disease in Peripheral Artery Disease: Characteristics, Consequences and Prevalence. Review of Endovascular Revascularization.
This report reviews the literature on BTA disease. BTA disease prevalence in CLI patients and limbs for the 2020-2040 period is included. The number of patients and limbs with MAC and thrombus in the BTA territory is estimated for 2020-2040. The current and potential U.S. market for endovascular treatment of BTA disease for the 2020-2040 period is included.
Additional information: https://www.thesagegroup.us/reports/below-the-ankle-disease-in-peripheral-artery-disease-characteristics-consequences-and-prevalence-review-of-endovascular-revascularization/.
THE SAGE GROUP, a research and consulting company, specializes in arterial and venous disease in the lower limbs.
Additional information: www.thesagegroup.us
SOURCE: THE SAGE GROUP
THE SAGE GROUP, Beaufort SC
Mary Yost, (404) 520-6652
yost@thesagegroup.us